Trial Profile
A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Neoantigen DNA vaccine AstraZeneca/Washington University School of Medicine (Primary) ; Nivolumab (Primary) ; Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary)
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- 03 Aug 2022 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 19 Apr 2022 Planned End Date changed from 10 Jan 2024 to 22 Jun 2022.